Rare Disease Trial, Recruiting (NCT06353620)

Rare Disease Trial, Recruiting NCT06353620 Sponsor: IRCCS Eugenio Medea Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06353620 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with focal epilepsy, generalized epilepsy, Angelman syndrome, or Dup15q, confirmed by a specialist
You have had at least one brain MRI scan that includes a specific type of detailed 3D imaging (called 3D T1)
You have had at least one high-definition EEG brain recording using 128 sensors/channels
You are between 6 and 75 years old at the time of the study evaluation
You are able to take part in a series of tests that assess memory, thinking, and other brain functions (called a neuropsychological evaluation)

Who may not be able to join:

Your epilepsy is caused by blood vessel problems or by brain tumors that are not considered low-grade (confirm with trial site)
You are younger than 6 or older than 75 years of age
Your brain MRI scan is incomplete or does not include the specific 3D T1 imaging type required
You have not had a 128-channel high-definition EEG recording
You are unable to participate in the thinking and memory assessment tests

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gian Marco Duma, IRCCS E. Medea

Phone: +39 0438414248

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06353620

Sponsor: IRCCS Eugenio Medea

Phase: Not Applicable

Status: Recruiting

Condition: Rare Disease

Trial contact: +39 0438414248

More information: https://clinicaltrials.gov/study/NCT06353620

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with focal epilepsy, generalized epilepsy, Angelman syndrome, or Dup15q, confirmed by a specialist
You have had at least one brain MRI scan that includes a specific type of detailed 3D imaging (called 3D T1)
You have had at least one high-definition EEG brain recording using 128 sensors/channels
You are between 6 and 75 years old at the time of the study evaluation
You are able to take part in a series of tests that assess memory, thinking, and other brain functions (called a neuropsychological evaluation)

Who may not be able to join:

Your epilepsy is caused by blood vessel problems or by brain tumors that are not considered low-grade (confirm with trial site)
You are younger than 6 or older than 75 years of age
Your brain MRI scan is incomplete or does not include the specific 3D T1 imaging type required
You have not had a 128-channel high-definition EEG recording
You are unable to participate in the thinking and memory assessment tests

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Eugenio Medea

Registry

ClinicalTrials.gov

Start date

13 February 2024

Est. completion

18 March 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Differences in the network coherence values in theta and alpha band after treatment; Stability of the alpha frequency band in the EEG activity; Correlation of neural excitation and memory performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov